Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy
IntroductionActivating the aryl hydrocarbon receptor upon exposure to environmental pollutants promotes development of breast cancer stem cell (CSCs). BCL-2 family proteins protect cancer cells from the apoptotic effects of chemotherapeutic drugs. However, the crosstalk between AhR and the BCL-2 fam...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , |
| التنسيق: | article |
| منشور في: |
2022
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://dx.doi.org/10.1016/j.jare.2022.10.006 https://www.sciencedirect.com/science/article/pii/S209012322200234X http://hdl.handle.net/10576/41421 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1857415085123698688 |
|---|---|
| author | Abdullah, Al-Dhfyan |
| author2 | Alaiya, Ayodele Al-Mohanna, Falah Attwa, Mohamed W AlAsmari, Abdullah F Bakheet, Saleh A Korashy, Hesham M. |
| author2_role | author author author author author author |
| author_facet | Abdullah, Al-Dhfyan Alaiya, Ayodele Al-Mohanna, Falah Attwa, Mohamed W AlAsmari, Abdullah F Bakheet, Saleh A Korashy, Hesham M. |
| author_role | author |
| dc.creator.none.fl_str_mv | Abdullah, Al-Dhfyan Alaiya, Ayodele Al-Mohanna, Falah Attwa, Mohamed W AlAsmari, Abdullah F Bakheet, Saleh A Korashy, Hesham M. |
| dc.date.none.fl_str_mv | 2022-10-26 2023-03-29T10:12:22Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://dx.doi.org/10.1016/j.jare.2022.10.006 Al-Dhfyan, A., Alaiya, A., Al-Mohanna, F., Attwa, M. W., AlAsmari, A. F., Bakheet, S. A., & Korashy, H. M. (2022). Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy. Journal of Advanced Research. 2090-1232 https://www.sciencedirect.com/science/article/pii/S209012322200234X http://hdl.handle.net/10576/41421 2090-1224 |
| dc.language.none.fl_str_mv | en |
| dc.publisher.none.fl_str_mv | Elsevier |
| dc.rights.none.fl_str_mv | http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | AhR/CYP1A1 Breast cancer stem cells In vivo mice BCL-2 Proteomics Venetoclax |
| dc.title.none.fl_str_mv | Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | IntroductionActivating the aryl hydrocarbon receptor upon exposure to environmental pollutants promotes development of breast cancer stem cell (CSCs). BCL-2 family proteins protect cancer cells from the apoptotic effects of chemotherapeutic drugs. However, the crosstalk between AhR and the BCL-2 family in CSC development remains uninvestigated. ObjectivesThis study explored the interaction mechanisms between AhR and BCL-2 in CSC development and chemoresistance. MethodsA quantitative proteomic analysis study was performed as a tool for comparative expression analysis of breast cancer cells treated by AhR agonist. The basal and inducible levels of BCL-2, AhR, and CYP1A1 in vitro breast cancer and epithelial cell lines and in vivo mice animal models were determined by RT-PCR, Western blot analysis, immunofluorescence, flow cytometry, silencing of the target, and immunohistochemistry. In addition, an in silico toxicity study was conducted using DEREK software. ResultsActivation of the AhR/CYP1A1 pathway in mice increased EpCAMHigh/CD49fLow CD61+ luminal progenitor-like cells in early tumor formation but not in advanced tumors. In parallel, a chemoproteomic study on breast cancer MCF-7 cells revealed that the BCL-2 protein expression was the most upregulated upon AhR activation. The crosstalk between the AhR and BCL-2 pathways in vitro and in vivo modulated the CSCs features and chemoresistance. Interestingly, inhibition of BCL-2 in mice by venetoclax (VCX) increased EpCAMHigh/CD49fLow CD61+ luminal progenitor-like cells, causing inhibition of epithelial lineage markers, disruption of mammary gland branching and induced the epithelial-mesenchymal transition in mammary epithelial cells (MECs). The combined treatment of VCX and AhR antagonists in mice corrected the abnormal differentiation in MECs and protected mammary gland branching and cell identity. ConclusionsThis is the first study to report crosstalk between AhR and BCL-2 in breast CSCs and provides the rationale for using a combined treatment of BCL-2 inhibitor and AhR antagonist for more effective cancer prevention and treatment. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | qu_6867a95030e5347fe10dc44d9d54ed13 |
| identifier_str_mv | Al-Dhfyan, A., Alaiya, A., Al-Mohanna, F., Attwa, M. W., AlAsmari, A. F., Bakheet, S. A., & Korashy, H. M. (2022). Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy. Journal of Advanced Research. 2090-1232 2090-1224 |
| language_invalid_str_mv | en |
| network_acronym_str | qu |
| network_name_str | Qatar University repository |
| oai_identifier_str | oai:qspace.qu.edu.qa:10576/41421 |
| publishDate | 2022 |
| publisher.none.fl_str_mv | Elsevier |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| spelling | Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapyAbdullah, Al-DhfyanAlaiya, AyodeleAl-Mohanna, FalahAttwa, Mohamed WAlAsmari, Abdullah FBakheet, Saleh AKorashy, Hesham M.AhR/CYP1A1Breast cancer stem cellsIn vivo miceBCL-2ProteomicsVenetoclaxIntroductionActivating the aryl hydrocarbon receptor upon exposure to environmental pollutants promotes development of breast cancer stem cell (CSCs). BCL-2 family proteins protect cancer cells from the apoptotic effects of chemotherapeutic drugs. However, the crosstalk between AhR and the BCL-2 family in CSC development remains uninvestigated. ObjectivesThis study explored the interaction mechanisms between AhR and BCL-2 in CSC development and chemoresistance. MethodsA quantitative proteomic analysis study was performed as a tool for comparative expression analysis of breast cancer cells treated by AhR agonist. The basal and inducible levels of BCL-2, AhR, and CYP1A1 in vitro breast cancer and epithelial cell lines and in vivo mice animal models were determined by RT-PCR, Western blot analysis, immunofluorescence, flow cytometry, silencing of the target, and immunohistochemistry. In addition, an in silico toxicity study was conducted using DEREK software. ResultsActivation of the AhR/CYP1A1 pathway in mice increased EpCAMHigh/CD49fLow CD61+ luminal progenitor-like cells in early tumor formation but not in advanced tumors. In parallel, a chemoproteomic study on breast cancer MCF-7 cells revealed that the BCL-2 protein expression was the most upregulated upon AhR activation. The crosstalk between the AhR and BCL-2 pathways in vitro and in vivo modulated the CSCs features and chemoresistance. Interestingly, inhibition of BCL-2 in mice by venetoclax (VCX) increased EpCAMHigh/CD49fLow CD61+ luminal progenitor-like cells, causing inhibition of epithelial lineage markers, disruption of mammary gland branching and induced the epithelial-mesenchymal transition in mammary epithelial cells (MECs). The combined treatment of VCX and AhR antagonists in mice corrected the abnormal differentiation in MECs and protected mammary gland branching and cell identity. ConclusionsThis is the first study to report crosstalk between AhR and BCL-2 in breast CSCs and provides the rationale for using a combined treatment of BCL-2 inhibitor and AhR antagonist for more effective cancer prevention and treatment.- King Faisal Specialist Hospital and Research Centre - grant No. RAC 2130040 - Qatar University - IRCC-2022-484Elsevier2023-03-29T10:12:22Z2022-10-26Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://dx.doi.org/10.1016/j.jare.2022.10.006Al-Dhfyan, A., Alaiya, A., Al-Mohanna, F., Attwa, M. W., AlAsmari, A. F., Bakheet, S. A., & Korashy, H. M. (2022). Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy. Journal of Advanced Research.2090-1232https://www.sciencedirect.com/science/article/pii/S209012322200234Xhttp://hdl.handle.net/10576/414212090-1224enhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:qspace.qu.edu.qa:10576/414212024-07-23T13:52:52Z |
| spellingShingle | Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy Abdullah, Al-Dhfyan AhR/CYP1A1 Breast cancer stem cells In vivo mice BCL-2 Proteomics Venetoclax |
| status_str | publishedVersion |
| title | Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy |
| title_full | Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy |
| title_fullStr | Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy |
| title_full_unstemmed | Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy |
| title_short | Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy |
| title_sort | Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy |
| topic | AhR/CYP1A1 Breast cancer stem cells In vivo mice BCL-2 Proteomics Venetoclax |
| url | http://dx.doi.org/10.1016/j.jare.2022.10.006 https://www.sciencedirect.com/science/article/pii/S209012322200234X http://hdl.handle.net/10576/41421 |